-
Ganxi Biologics announced that the Phase 1/2 registration clinical trial of GC007g for the treatment of B-ALL has successfully entered the Phase 2 study phase and has completed the dosing of the first patient
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Global clinical-stage biopharmaceutical company Ganxi Biotechnology Group (NASDAQ: GRCL; "Ganxi Biologics") announced that the Phase 1/2 registration clinical trial in China to comprehensively evaluate the efficacy of GC007g in the treatment of relapsed/refractory acute B-cell leukemia (r/r B-ALL) has successfully entered the Phase 2 study stage, and the first enrolled patient has been dosed.
-
Recently, these two multinational pharmaceutical companies launched acquisitions, with a total amount of nearly 2 billion US dollars!
Time of Update: 2022-10-25
Conclusion In general, the purpose of continuous mergers and acquisitions of large pharmaceutical companies mainly includes strengthening their R&D pipelines, investing in blockbuster drugs under research or about to be launched, complementarity of product portfolios, and synergistic economies of scale.
-
The global Phase 3 RAPID clinical trial of Etripamil nasal spray in patients with paroxysmal supraventricular tachycardia (PSVT) has achieved positive results
Time of Update: 2022-10-25
001) ● Safety and tolerability data are consistent with previous studies to support out-of-hospital self-administration of Etripamil in patients with PSVT ● Pooled analysis showed that self-administration of etripamil in patients with PSVT significantly reduced the number of additional medical interventions and emergency department visits ● Milestone plans to submit a new drug application to the U.
-
The latest research results of GT19715, a new C-Myc/GSPT1 dual-target degrader of Pioneer Pharmaceutical, were published, which has good anti-acute myeloid leukemia and lymphoma efficacy
Time of Update: 2022-10-25
The killing effect of GT19715, a novel C-Myc/GSPT1 dual-target degrader developed by Pioneer Pharmaceutical, on acute myeloid leukemia (AML) and lymphoma was demonstrated.
The killing effect of GT19715, a novel C-Myc/GSPT1 dual-target degrader developed by Pioneer Pharmaceutical, on acute myeloid leukemia (AML) and lymphoma was demonstrated.
-
This article takes you through liposomal drug delivery systems
Time of Update: 2022-10-25
3 Injection method Preparation process: The membrane and the drug are dissolved in an organic solvent, and then the oil phase is injected into the aqueous phase (which may contain water-soluble drugs) at a uniform speed, and the continuous stirring is used, and the vortex generated by the stirring is used to promote the arrangement of lipids to form liposomes.
-
Alphyn announced that enrollment for a Phase 2a clinical trial is more than halfway through
Time of Update: 2022-10-25
js?cdnversion='+~(-new Date()/36e5)]; Alphyn Biologics, a clinical-stage dermatology company developing the first of its kind to treat multi-target drug therapies, today announced that it is more than halfway through its Phase 2a clinical trial of AB-101a for mild to moderate atopic dermatitis (AD).
-
Sirnaomics will report on the latest developments of the GalAhead® therapy delivery platform and related projects at two future industry academic conferences
Time of Update: 2022-10-25
Sirnaomics Ltd. (the "Company", "Sirnaomics", stock code: 2257. HK), is an industry-leading biopharmaceutical company focused on the exploration and development of RNAi therapeutics. Sirnaomics annou
-
Yingshi Biotech announced the IN10018 clinical research data at the 2022 International Melanoma Society (SMR) Annual Meeting
Time of Update: 2022-10-25
Yingshi Biologics, a global innovative drug R&D company focused on breaking through drug resistance in solid tumors, announced that at the 19th Annual Meeting of the International Melanoma Society (S
-
Vaccination is like "drinking milk tea"! Take stock of the advantages and difficulties of inhalation seedlings
Time of Update: 2022-10-20
While the mucosal immune system plays a key role in protecting the respiratory tract from pathogenic invasion, an excessive immune response can damage the lungs and lead to the development of (antibody-dependent) respiratory diseases.
-
New ideas and progress in targeting "undruggable" transcription factors
Time of Update: 2022-10-20
Transcription factors play a fundamental role in selective gene regulation, so they have a higher specific disease regulatory capacity than upstream signaling proteins such as kinases, and because gene targets are specifically controlled by DNA binding, a single TF usually regulates only a limited set of gene targets, so this inhibitor is not prone to compensatory resistance mechanisms common to other drugs.
-
Conrad Biopharma announced that a key clinical trial in China of CBP-201 for the treatment of moderate to severe atopic dermatitis successfully met the primary endpoint and all key secondary endpoints
Time of Update: 2022-10-20
About this clinical trial The China pivotal clinical trial of CBP-201 for the treatment of moderate to severe atopic dermatitis (NCT05017480) is an ongoing multicenter, randomized, double-blind, parallel-group, placebo-controlled trial whose primary purpose is to evaluate the efficacy and safety of the drug, and the study will be divided into two phases.
-
A new CRO company was added to the ChiNext board, and the company had nearly 200 pharmaceutical R&D personnel at the end of 2021
Time of Update: 2022-10-20
【Pharmaceutical Network Enterprise News】On October 13, news that a new CRO enterprise was added to the Growth Enterprise Market, namely Anhui Wanbang Pharmaceutical Technology Co. , Ltd. (hereinafter
-
Pembrolizumab helps patients with multiple types of advanced tumors achieve long-term survival
Time of Update: 2022-10-20
At the 2022 European Medical Oncology (ESMO) Congress that concluded on September 13, the five-year survival follow-up data of multiple immunotherapy combined with chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC) were released, including Merck's PD-1 inhibitor pembrolizumab (commonly known as "K drug") combined with chemotherapy.
-
Low-dose drug content uniformity prediction and process selection
Time of Update: 2022-10-20
In recent years, scientists in the field of drug discovery have studied many very effective small molecule drug candidates, but the pharmacological effects of such drugs can be very low effective dos
-
The world's first clinical study of immunotherapy for small cell lung cancer published in the international journal JAMA, and the positive results of H drug Hans-shaped (R) combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer were released
Time of Update: 2022-10-20
ASTRUM-005 study is a phase III clinical study of anti-PD-1 monoclonal antibody H drug independently developed by Henlius Hans-form ® (serplulimab) combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), after Professor Cheng Ying reported the results for the first time at the 2022 ASCO Annual Meeting, which attracted widespread attention from global peers, and now has once again appeared on the international top academic stage, reflecting the high recognition of the international academic community.
-
The clinical results of Proclolamide in the treatment of AR+ breast cancer phase Ib were published in the international journal EJC
Time of Update: 2022-10-20
The study, published in the journal EJC, is Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis 。 The study was designed to evaluate the initial efficacy and safety of proclolamide monotherapy in patients with AR+ mBC and to determine the recommended dose for a phase II clinical trial.
-
Nellik? The results of phase I/II clinical studies were published in the international authoritative journal "Journal of Hematology & Oncology", verifying the potential of best-in-class
Time of Update: 2022-10-19
Ascentage Pharma (6855. HK) announced on September 21 that the phase I and phase II clinical results of the company's core variety orebatinib (HQP1351, trade name: Nerix) in the treatment of drug-res
-
Ascletis announced the completion of the first patient dosing of ASC22 (Envolimab) for the functional cure of chronic hepatitis B in the Phase IIb Extended Cohort Study
Time of Update: 2022-10-19
e. , HBsAg clearance) by blocking the PD-1/PD-L1 pathway 。 In June 2022, Ascletis orally presented the latest results of the Phase IIb clinical trial of ASC22 in patients with chronic hepatitis B at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 (ILC 2022), which showed that 42.
-
Harbour Bio Pharmaceuticals announced the completion of the first subject dosing of a new generation of anti-TSLP fully human monoclonal antibodies
Time of Update: 2022-10-19
HK) announced on September 27 that it and Kolombateo (a subsidiary of Kelun Pharmaceutical), jointly developed a new generation of anti-TSLP fully human monoclonal antibody HBM9378 (KB378), which completed the dosing of the first subject in a phase I clinical trial in China.
-
When will the 10 billion NASH market usher in a new "break"?
Time of Update: 2022-10-13
According to incomplete statistics, a number of new NASH drugs around the world have made new progress this year: In January, 89bio announced that its NASH therapy pegozafermin (formerly known as BIO89-100) had achieved positive results in a Phase 1b/2a proof-of-concept clinical trial.
